$$ Grant Life Sciences! Volumen lügt nicht! $$ - 500 Beiträge pro Seite

[calibra21]

US-Kürzel: GLIF
WKN: A0F6J8
Handelbar in USA und Berlin
Totalverlust möglich.
Dies stellt keine Kauf- oder Verkaufsempfehlung dar, sondern spiegelt nur meine Meinung wieder. Jeder handelt auf eigenes Risiko.

Gestern veröffentlichte Grant Life Sciences diese Meldung:

http://biz.yahoo.com/bw/060412/20060412005430.html?.v=1

Diagnostic Technologies Ltd. möchte die Krebsdiagnosetechnologie von Grant life weiterentwickeln und kommerzialisieren.

Jetzt nimmt GLIF endlich Cash ein.

...The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercializationof the resulting product...

Einmalzahlung + fortwährende Zahlungen auf verkaufte Produkte werden in dem Memorandum of Understanding (MOU) genannt.

Wobei meiner Meinung nach das Wichtigste die fortwährenden Zahlungen sind, da diese dauerhaftes Revenue versprechen sollten.

Der Meinung bin nicht nur ich!

12,224,135 Aktien wurden umgesetzt! Und das bei einem Free-Float von gerade mal 43,180,000 Aktien (lt. yahoo.com)
http://finance.yahoo.com/q/ks?s=GLIF.OB

Über 25 % aller handelbaren Aktien wurden somit an nur einem Tag umgesetzt.

Wer mich kennt kennt auch mein Motto:\"Volumen lügt nicht!\"



Ich für meinen Teil erwarte für die nächsten Wochen einen heftigen Kursaufschlag.

[fs2003]

[aLoNe]

lasst mich rein hier

1. hab ich auch schon hier recherchiert

2. ist mein alter schwede Calibra auch on board

[aLoNe]

heute schon 2 news und gerade die von den 2 am meisten gelesen USA stock "Blättern"


OTCPicks.com: Daily Market Movers Digest Stock Alerts, Wednesday, April 12th, BOCX, PAPO, NPWS, GLIF, IFLB, CBAY 4/13/2006 8:07:37 AM
Stockguru.com: Guru Alerts for Thursday, April 13, 2006 CVAS, MCDG, ARET, GLIF. 4/13/2006 7:31:53 AM



GRANT LIFE SCIENCES, INC. (OTCBB: GLIF) "Up 8% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/GLIF.php

Grant Life Sciences Inc. (OTCBB: GLIF) develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious, or economic reasons. Further information is available at: www.grantlifesciences.com.

GLIF News:

April 12 - Grant Life Sciences enters into a Memorandum of Understanding with Diagnostic Technologies Ltd. ('DTL') to develop and commercialize Grant's cervical cancer-diagnostic technology

The proposed deal would include upfront payment of $250,000 to Grant, plus ongoing royalties upon commercialization of the resulting product; also, DTL will conduct and fund all development costs, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer diagnostic technology

Grant Life Sciences Inc. (OTC Bulletin Board: GLIF) announced today that it has entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the MOU.

A definitive licensing agreement will be signed following appropriate due diligence and a feasibility test. Upon signing, DTL will immediately assume all of the costs associated with turning Grant's core technology related to cervical-cancer diagnostics into a commercially viable product. The diagnostic product based on Grant's technology will augment and complement DTL's suite of diagnostics aimed at the women's health market. Stan Yakatan, Grant's Chairman, together with DTL's Chairman, were instrumental in structuring this MOU, recognizing the considerable synergy of the relationship between the companies.

"This event, once consummated, will represent a most important milestone in the evolution of our company," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist. "To date, we have been hampered in our development of our cervical cancer-technology because of capital constraints. The large costs of development, as well as the considerable expenses associated with being a publicly traded company, have hampered our ability to expedite final development of our core technology. This affiliation with DTL will help us accomplish many of our goals and more readily assure success and hoped-for shareholder value appreciation."

"We are happy with the opportunity to extend our current knowledge in developing diagnostic tools and means in the field of women's health to the field of cervical cancer and to fast-forward development and commercialization of a diagnostic product based on Grant's cervical cancer diagnosis technology," said Hamutal Meiri, Ph.D., Chief Executive Officer of DTL. "We hope that their technology will enable the detection of the presence of antibodies produced only by cancer-causing HPV-types and profile them." According to the National Cancer Institute there are some 100 types of HPV. However, only about 7 to 15 of these appear to cause cervical cancer, with certain HPV-types especially virulent in this regard. Cancer-causing HPV-types express certain unique proteins that help trigger the disease. The parties to the MOU believe that the product developed using Grant's technology can distinguish these cancer-causing proteins from those made by non-cancer-causing HPV-types. DTL therefore expects that using Grant's technology will enable it to determine whether a woman has cervical cancer or pre-cervical cancer conditions.

"Upon consummation of this partnership with DTL, Grant will have the 'luxury' of being able to focus its efforts on boosting revenues from sales in Asia of its rapid AccuDx tests for Malaria and Dengue Fever," added Stan Yakatan, Chairman of Grant. "These products, along with its rapid AccuDx tests for HIV-1 and HIV-2, represent an impressive product portfolio, and Grant will be able to look to drive new-business development for Grant Life Sciences in Asia. In addition, the market for cervical cancer testing is enormous, and DTL intends to carry a focused and controlled development of this innovative non-invasive, protein-based diagnostic test."

According to the American Cancer Society, the human papillomavirus (HPV) causes virtually all cervical cancer. Through its proprietary protein-based technology, the assay under development is intended to look at HPV in a fashion that identifies cervical cancer, its precursors or the likelihood of its presence. This immunotest includes antibodies especially associated with HPV-caused neoplasias or cancers that are detected with synthetic, proprietary peptides or amino acid sequences derived from certain proteins in the human papillomavirus.

About Diagnostic Technologies Ltd. (DTL)

DTL, based in Yokneam Illit, Israel, is a private company that has licensed from Technion a technology for using a highly sensitive immunoassay for the prediction of the risk to preeclampsia based on the quantitative determination of placental protein 13 (PP13) in maternal serum for prediction pregnancy disorders. The current test is aimed for the prediction of the risk for preeclampsia. According to the CDC, preeclampsia affects five to seven percent of all pregnant women and represents a serious challenge for obstetricians and prenatal and diagnostic laboratories. This threatening disorder can result in: loss of life; blindness; motor and mental disorders or premature newborns; pregnancy hypertension; and kidney, liver & cardiovascular malfunctioning. It is estimated that nearly $30 billion is spent today in healthcare costs to treat women with preeclampsia and their newborns. The company's in vitro ELISA-based test utilizes a simple blood test for the early prediction of preeclampsia, and it is now in clinical trials. TEUZA, an Israeli venture fund, is the major investor in the Company. On Jan. 31, 2006, PerkinElmer, Inc. (NYSE: PKI), a world leader in Health Sciences and Photonics, announced that it has secured the exclusive global rights to PP13 for identifying patients at risk for preeclampsia developed by DTL.



und

Grant Life Sciences, Inc. (OTCBB:GLIF) traded as much as 4.00% over open on Wednesday.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test. The diagnostic assay being developed by the Company has initial clinical validation indicating superior sensitivity and specificity in detecting cervical cancer and its precursors, a disease that kills in excess of 300,000 women annually. Currently there are more than 120 million cervical screening tests administered annually in the U.S. and Europe. More than 120 million eligible women 20+ years old in developed nations still do not get Pap smears, and globally more than 1.7 billion over the age of 20 have never been checked due to cultural, religious or economic reasons. Further information is available at: www.grantlifesciences.com.





danke cali

[aLoNe]

du hast barchart.com noch vergessen


Composite Indicator
Trend Spotter TM Buy

Short Term Indicators
7 Day Average Directional Indicator Buy
10 - 8 Day Moving Average Hilo Channel Buy
20 Day Moving Average vs Price Buy
20 - 50 Day MACD Oscillator Buy
20 Day Bollinger Bands Hold

Short Term Indicators Average: 80% - Buy
20-Day Average Volume - 2100810

Medium Term Indicators
40 Day Commodity Channel Index Buy
50 Day Moving Average vs Price Buy
20 - 100 Day MACD Oscillator Buy
50 Day Parabolic Time/Price Sell

Medium Term Indicators Average: 50% - Buy
50-Day Average Volume - 5917920

Long Term Indicators
60 Day Commodity Channel Index Hold
100 Day Moving Average vs Price Buy
50 - 100 Day MACD Oscillator Buy

Long Term Indicators Average: 67% - Buy
100-Day Average Volume - 5634079

Overall Average: 72% - Buy

Price Support Pivot Point Resistance

0.0260 0.0180 0.0270 0.0360

[aLoNe]

cali, hast du RT?

ask ist anscheinend schon bei 0,035!

[aLoNe]

und die nächste news kam grad raus


Wall Street News Alert: Hot Stocks on the Move! April 13, 2006

Weston, FLA., Apr 13, 2006 (M2 PRESSWIRE via COMTEX) -- Wall Street News Alert's "stocks to watch" this morning are: Positron Corporation (OTCBB: POSC), Grant Life Sciences Inc. (OTCBB: GLIF), Discovery Laboratories, Inc. (NASDAQ: DSCO), Omnicare, Inc. (NYSE: OCR) and Cephalon, Inc. (NASDAQ: CEPH).
Additional breaking news from Positron Corporation (OTCBB: POSC) should have the attention of aggressive investors and day traders again this morning! Yesterday after the stock markets closed, the company issued a press release announcing that after languishing in the clinical shadows for the last 10 years, rubidium is starting to catch the attention of nuclear medicine specialists. The radiopharmaceutical can thank the Centers for Medicare and Medicaid Services (CMS) for its revival.

The report should get the attention of investors! CMS, as of January 1, 2006, increased the reimbursement for myocardial PET perfusion imaging involving multiple studies at rest and/or stress. The new rate of $2,484.88 more than triples the 2005 rate of $735.77.

Joseph Oliverio, President of Positron stated, "The increase of reimbursement by CMS demonstrates the continued support of our government payers by promoting the increased utilization of PET as a first line test for detection of heart disease."

Investors should continue to research Positron! "There seems to be a general consensus -- at least in the nuclear cardiology community -- that rubidium PET might replace SPECT in patients who are under pharmacological stress, simply because it is so fast," said Dr. Marcelo DiCarli, chief of nuclear medicine and PET and co-director of cardiovascular imaging at Brigham and Women's Hospital. DiCarli has been using rubidium for several years to build the Boston hospital's PET program and today images between 1,100 and 1,200 cardiac patients annually with the tracer.

Rubidium-based cardiac PET has not only enhanced patient throughput with shorter scan times but has also proven beneficial for difficult-to-image patients. "Once you get into patients who are obese, we know what the limitations of SPECT are," DiCarli said. "Those patients who need to undergo pharmacological stress are those who are usually the sickest; those are the patients for whom (rubidium-based) PET provides a significant advantage."

Wall Street News Alert is continuing to place Aggressive Investors on alert to monitor the progress of Positron! Yesterday we brought to your attention the company's press release in which it just announced that it has finalized an agreement with the University of Texas at Houston and the Weatherhead PET Center headed by Dr. K. Lance Gould granting Positron a license to develop and commercialize an integrated comprehensive software system developed for the major diagnostic and management needs in coronary artery disease.

Prior to the latest press release, the stock closed yesterday at Thirteen cents a share.

For an in-depth profile of Positron Corporation, visit http://www.thenewssvc.com/POSC041106.html To view all of Wall Street News Alert's special early morning trading alerts for this morning, visit www.WallStreetNewsAlert.com, where you may also sign up to receive free email alerts in advance of our press releases being issued.

In case you are not familiar with the company: Positron Corporation designs, manufactures, markets and supports advanced medical imaging devices utilizing positron emission tomography (PET) technology under the trade name POSICAM systems. POSICAM systems incorporate patented and proprietary software and technology for the diagnosis and treatment of patients in the areas of cardiology, oncology and neurology. Positron Corporation offers unique combination of low cost technology and disease specific software solutions differentiating themselves from all other medical device manufacturers. POSICAM systems are in use at leading medical facilities, including the Weatherhead PET center at the University of Texas Health Science Center in Houston, Texas; The Heart Center of Niagara in Niagara Falls, New York; Beth Israel Medical Center, New York; Emory Crawford Long Hospital Carlyle Fraser Heart Center in Atlanta, Georgia; and Nishidai Clinic (Diagnostic Imaging Center) in Tokyo, Japan.

Grant Life Sciences Inc. (OTCBB: GLIF) up 4% on 12.2 million shares traded.

Grant Life Sciences Inc. develops products to improve the efficiency of detecting and diagnosing cervical cancer, including a sensitive, reliable, non-invasive, point-of-care test.

Grant Life Sciences Inc. recently announced that it has entered into a Memo of Understanding (MOU) with Israel-based Diagnostic Technologies Ltd. (DTL) related to Grant's cervical cancer-diagnostic technology (U.S. Patent No. 6,743,593). Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the MOU.

Discovery Laboratories, Inc. (NASDAQ: DSCO) up 6.7% on 3.6 million shares traded.

Discovery Laboratories, Inc. is a biotechnology company developing its proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory diseases. Discovery Laboratories, Inc. recently announced that management will be hosting a conference call to provide an update on the progress of the Surfaxin(r) New Drug Application.

Omnicare, Inc. (NYSE: OCR) up 1.8% on 2.4 million shares traded.

Omnicare, Inc. is a provider of pharmaceutical care for the elderly. In the companies latest news Omnicare, Inc. announced it will release its financial results for the first-quarter ended March 31, 2006, on Thursday, April 27, 2006, before the opening of trading on the New York Stock Exchange.

Cephalon, Inc. (NASDAQ: CEPH) up 2.3% on 2.5 million shares traded.

Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and marketing of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. Cephalon, Inc recently has scheduled its regular quarterly earnings conference call covering first quarter 2006 results for 5:00 p.m. EDT on Tuesday, May 2, 2006.

Commentary: "The Commerce Department reported that the trade deficit fell in February to 65.1 billion from an all time high of 68 billion in January, a drop of 4.1%. However, this is in line with expectations and nothing to ignore. Secretary of Commerce Carlos Gutierrez signed an agreement with China that will protect pirated movies and try to improve tariff barriers of U.S. exports like medical devices, direct food sales, and telecommunications equipment," Stated Sonja Rudd in Wall Street News Alert's daily commentary continued at: http://www.WallStreetNewsAlert.com.

Let Wall Street News Alert help advertise for your company using our effective awareness campaigns. If you're Interested in telling your story, we can help. Contact us at [e-mail]

WSNA's email alert service is free to those investors who sign up on the WSNA home page. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to Special Situation companies that have the potential of showing increased activity. The Wall Street News Alert home page has experienced over 50 million hits. To subscribe to this free service, visit the Wall Street News Alert home page at http://www.wallstreetnewsalert.com and select the "join now" button.

*** Wall Street News Alert is not affiliated with faxes bearing names such as: Wall Street Stock Alert, Wall Street Investor Alert, Wall Street News Alert or any other fax using various combinations of the generic words Wall Street! If you receive any such fax, please do not contact us at www.wallstreetnewsalert.com. You may wish to inquire about the fax, with the CEO of the company that the fax is written about ***

Wall Street News Alert is a division of Wall Street Capital Funding LLC (WSCF). WSCF is not a registered broker/dealer and may not sell, offer to sell or offer to buy any security. WSCF profiles are not a solicitation or recommendation to buy, sell or hold securities. An offer to buy or sell can be made only with accompanying disclosure documents from the company offering or selling securities and only in the states and provinces for which they are approved. The material in this release is intended to be strictly informational. The companies that are discussed in this release have not approved the statements made in this release nor approved the timing of this release. All statements and expressions are the sole opinion of WSCF and are subject to change without notice. Information in this release is derived from a variety of sources including that company's publicly disseminated information, third parties and WSCF research. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. WSCF disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. The release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies' discussed in this release is highly speculative and carries a high degree of risk. WSCF is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment if they make a purchase in WSCF profiled stocks.

This profile is not without bias, and is a paid release. WSCF has been compensated for dissemination of company information on behalf of one or more of the companies mentioned in this release. (WSCF has been compensated Twenty Five Thousand Dollars for coverage of Positron Systems Inc., (OTCBB: POSC), by a third party (CLX & Associates Inc.), who is non-affiliated and may hold a significant position in the stock, for services provided including dissemination of company information in this release. WSCF holds no shares of the stock. WSCF may receive additional compensation for extension of its services. Any additional compensation will be disclosed at such time that WSCF is aware of a clients desire to extend the original services. WSCF may have received shares of a company profiled in this release prior to the dissemination of the information in this release. WSCF may immediately sell some or any shares in a profiled company held by WSCF and may have previously sold shares in a profiled company held by WSCF. WSCF's services for a company may cause the company's stock price to increase, in which event WSCF would make a profit when it sells its stock in a company. In addition, WSCF's selling of a company's stock may have a negative effect on the market price of the stock.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WSCF undertakes no obligation to update such statements.

CONTACT: Wall Street News Alert e-mail: [e-mail] WWW: http://www.wallstreetnewsalert.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [e-mail].




(C)1994-2006 M2 COMMUNICATIONS LTD

**********************************************************************
As of Sunday, 04-09-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-16-2006 for CEPH @ $74.59.

As of Sunday, 04-09-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated an UPTREND on 10-28-2005 for DSCO @ $7.17.

As of Sunday, 04-09-2006 23:59, the latest Comtex SmarTrend(SM) Alert, an automated pattern recognition system, indicated a DOWNTREND on 03-29-2006 for OCR @ $56.93.

(C) 2006 Comtex News Network, Inc. All rights reserved.

[aLoNe]

und ab gehts

[aLoNe]

Detailed Quote Snapshot 04/13/2006 09:36 AM
Last:

0.029 GLIF - GRANT LIFE SCIENCES INC
Change:

% Change:

% High:

0.029 Low:

0.028 Volume:

266,000

[Cyberdiver_8]

Stock Trading Alert for Wednesday, July 12th
DC Brands International, Inc. (PINKSHEETS: DCBI), HiEnergy Technologies, Inc. (OTCBB: HIET), Xechem International, Inc. (OTCBB: XKEM), Grant Life Sciences, Inc. (OTCBB: GLIF):

Investors, have a look at DC Brands International, Inc. (PINKSHEETS: DCBI), provider of the energy drink "Dickens Energy Cider". The company announced Tuesday that it has a team of five people from their headquarters heading to Minnesota to launch their new distributors starting this weekend.

DC Brands said the chain of eight distributors, now under the heading of recently signed Minnesota Distributor, The Bernick Group, will receive their initial shipments before the week is over and had committed to an aggressive launch and crew drive scheduled for the entire following two weeks.

The company said that Richard Muscarella, DC Brands International VP of Sales, is in the process of interviewing over 60 applicants this week who are already highly experienced in the industry, and will narrow down to find the best two or three people to provide more full-time local representation to support The Bernick Group on a continuing basis and to become brand advocates for DC Brands products throughout the state.

This could be very good news for investors, as Muscarella said the company plans to "make a very large splash in Minnesota" this month, and added he expects the relationship to generate in excess of $100,000 per month within approximately 90 days from this week's launch.

DC Brands International, Inc. (PINKSHEETS: DCBI) is currently trading at around 9 cents a share.

Other stocks to watch:

Homeland security diagnostic technology company, HiEnergy Technologies, Inc. (OTCBB: HIET), announced Tuesday that the company will jointly market and sell its portable, suitcase-borne SIEGMA(TM) explosive detection and confirmation system with Ingersoll Rand Security Technologies, part of Ingersoll Rand Company Limited.

HIET closed Tuesday at $0.36.

Xechem International, Inc. (OTCBB: XKEM) issued a press release on Tuesday congratulating its subsidiary, Xechem Pharmaceuticals Nigeria, on the successful launch of NICOSAN(TM), the company's new Sickle Cell drug at a ceremony held on July 6th at Xechem Park in Nigeria.

XKEM closed Tuesday at $0.046.

Grant Life Sciences, Inc. (OTCBB: GLIF) announced Tuesday that the company had extended its Memorandum of Understanding with Israel based Diagnostic Technology Ltd., related to Grant Life Sciences cervical cancer-diagnostic technology, through Sept. 2006 GLIF closed Tuesday at $0.032.

About eLocity Inc.: eLocity owns and operates three financial websites for investors:

-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.

-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers." We rank stocks on volume, message board activity, sentiment and trend forecast.

-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.

Sign up for FREE at any of the sites above.

The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company." The company received compensation for this service for DC Brands International, Inc. (Public Company). The compensation is one thousand dollars from a non-affiliated third party, Alex Consulting Inc. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.

The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.

The company relies exclusively on information gathered on the Public Company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the Public Company in order to allow the investor to form his or her own opinion regarding the Public Company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.

Investing in the Public Company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.

The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.



Source: Market Wire (July 12, 2006 - 7:10 AM EDT)

[as25]

Ask ist immer noch auf 0,032 !!!

Alter Pusher

[Obertor]

Antwort auf Beitrag Nr.: 22.542.222 von as25 am 12.07.06 14:08:07

Das glaube ich auch, das ist ein Zock für Zocker und somnst ist gar nichts dahinter

Tor

[calibra21]

Antwort auf Beitrag Nr.: 24.203.785 von Obertor am 26.09.06 10:13:23

Nein, überhaupt nicht

[Roulett.Profi]

Hi,
die Besten Thrads,
wo wenigstens im EingangsPosting steht
um was es überhaubt geht,
liegen brach
und der Kindergarten erfreut sich an sinnlosen-
Neu eröffneten Traed-

Traurig aber war


oder was sagt ihr zwei Brüder dazu (C+S)

[Roulett.Profi]

ohne Religion
und vorallem ohne Kevi Dingsbums und Consorten

[AlexanderDD]

so, gestern sind ja News raus, und in ein Paar Tagen sollen ja weitere News kommen

Grant Life Sciences Enters into Memorandum of Understanding (MOU) with i+MED Laboratories Co. Ltd. to Distribute i+MED's Point-of-Care Rapid Diagnostic Tests Via Grant's Established Marketing Channels
Wednesday October 11, 9:00 am ET

LOS ANGELES--(BUSINESS WIRE)--"This is the third partnership we have announced in recent weeks, bearing strong testimony that we are aggressively executing Grant's new corporate strategy, which includes driving the sales of our partners' products through our own established, significant marketing channels."

ADVERTISEMENT
Dr. Hun-Chi Lin, President and Chief Scientist, Grant Life Sciences

Grant Life Sciences Inc. (OTC BB: GLIF - News) announced today that it has signed a Memorandum of Understanding (MOU) with Thailand-based i+MED Laboratories Co. Ltd. to distribute i+MED's point-of-care rapid diagnostic tests via Grant's established marketing channels in India, Taiwan, Indonesia, Mexico, Middle East and Africa and expand into other countries later.

The i+MED product portfolio to be distributed by Grant includes, but is not limited to, the following rapid tests: drugs of abuse, pregnancy, and infectious disease product lines.

"This is the third partnership we have announced in recent weeks, bearing strong testimony that we are aggressively executing Grant's new corporate strategy, which includes driving the sales of our partners' products through our own established, significant marketing channels," said Hun-Chi Lin, Ph.D., Grant's President and Chief Scientist.

About i+MED Laboratories

Founded in 2001, i+MED Laboratories Co. Ltd. (www.imed.co.th) is one of the leading diagnostics companies in Thailand. The company, which develops, manufactures and distributes high-quality 'rapid' tests for Asian markets, is 46 percent owned by the Thai government's SME Venture Capital Fund.

About Grant Life Sciences

Grant Life Sciences Inc., a development stage company, engages in the research, development, marketing, and sale of diagnostic kits for the screening, monitoring, and diagnosis of diseases with emphasis on women's health, infectious diseases, and cancers.

Forward-Looking Safe Harbor Statement

With the exception of historical information, the matters discussed in this press release are "forward-looking statements" that involve a number of risks and uncertainties. The actual future results of Grant Life Sciences could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rates and unanticipated events such as terrorist activities, results of clinical trials, and market acceptance of the Company's products. In some cases, "forward-looking statements" can be identified by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," or other comparable terminology. Although Grant Life Sciences believes that the expectations reflected in the "forward-looking" statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such "forward-looking statements" will be achieved. Grant Life Sciences undertakes no duty to update any of the "forward-looking statements," whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such "forward-looking statements." For further risk factors associated with our Company, review our SEC filings.


Contact:

Grant Life Sciences Inc.
Don Rutherford, 949-521-1232
CFO

[whyso]

Antwort auf Beitrag Nr.: 21.186.089 von calibra21 am 13.04.06 08:58:50

@Calibra-Gratulation für deine "Früherkennung" (13.04) im Fall Grant Life, wirklich beeindrückend wenn man der Verlauf diese Aktie etwas näher anschaut-ein echte volltreffer deinerseits

Viele steigende Grüße,
Whyso (der übrigens hier nicht investiert ist)